Roxera

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roxera

Property Description
Active ingredient Rosuvastatin calcium
Form Film-coated tablet (Oral route)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Lipid-modifying therapy
Origin Synthetic compound

What Type of Medicine is Roxera (Rosuvastatin)?

Roxera is a prescription-only medicine containing the active component Rosuvastatin calcium. It is classified pharmacologically as a HMG-CoA Reductase Inhibitor, placing it within the widely recognized group of medications known as Statins. This classification is clinically recognized for its essential role in mitigating the risk factors associated with cardiovascular disease. Statins function by reducing the synthesis of cholesterol in the liver.

As a newer-generation Statin, Roxera is a synthetic compound that differentiates itself from older analogues through its higher potency and distinct chemical structure. It is primarily used in scenarios requiring sustained management of elevated fat levels, such as when a patient is identified with primary hypercholesterolemia or mixed dyslipidemia.

Roxera's Form, Composition, and General Purpose

The medicinal product Roxera is presented as a single-ingredient product designed for oral administration in the physical form of a film-coated tablet. The composition is centered on the Rosuvastatin calcium active ingredient, integrated within a solid matrix of excipients. Rosuvastatin is approved for lowering high cholesterol levels in the blood.

The generalized therapeutic purpose of Roxera is to serve as a lipid-modifying therapy. By modulating the body’s internal production and clearance of fats, the drug aims to achieve a significant and lasting reduction in the concentration of low-density lipoprotein cholesterol (LDL-C) in the bloodstream. This function is foundational to the drug’s role in managing high blood fat levels and serves as a reliable tool in the preventative strategy against vascular changes.

What side effects are possible with Roxera?

Official Safety Profile and Adverse Reactions

The safety profile of Roxera (rosuvastatin) is officially documented by government regulatory bodies, detailing adverse reactions by frequency and the physiological system affected.

Adverse reactions are classified into categories reflecting their reported incidence:

  • Common reactions (occurring in 1/100 to 1/10 patients) include headache, myalgia (muscle pain), asthenia (weakness), nausea, constipation, abdominal pain, and new-onset diabetes mellitus.
  • Uncommon reactions include pruritus (itching), rash, and urticaria.
  • Rare reactions include pancreatitis, myopathy, rhabdomyolysis, and elevations in liver enzymes.
  • Reactions where the frequency is not known include immune-mediated necrotizing myopathy and severe cutaneous adverse reactions.

Major systems associated with adverse events include Musculoskeletal, Gastrointestinal, Nervous system, and Hepatobiliary disorders. Rosuvastatin is associated with rare, but serious, documented adverse reactions, such as rhabdomyolysis (severe muscle breakdown) and hepatitis or jaundice (liver inflammation).

Safety Restrictions and Special Populations

Official labeling mandates safety constraints, including a contraindication in patients with active liver disease (with unexplained, persistent transaminase elevations), severe renal impairment ( Creatinine Clearance < 30 mL/ min), and during pregnancy or lactation. Population-specific notes address the higher systemic exposure documented in patients of Asian descent, and specific considerations apply to older adults (70 years) and those with severe renal impairment.

Exposure-related patterns are also noted: proteinuria (of tubular origin) is reported to be generally transient and observed primarily in patients receiving higher doses.

Overdose and Emergency Response

Overdose and when to seek help for Roxera (Rosuvastatin)

Official regulatory information for Roxera overdosage focuses strictly on mandated emergency actions and supportive care, as no specific symptoms or clinical signs characteristic of an acute overdose have been officially documented. The United States FDA and European regulatory bodies do not define specific dose-related toxic factors for the drug.

Required Emergency Actions

Action Mandated by Regulators Details from Official Documents
Immediate Medical Attention Seek immediate medical attention for any suspected overdose. This action is required regardless of whether the patient is showing symptoms.
Contact Information Regulators advise calling your doctor, contacting a regional poison control centre, or going to the nearest hospital emergency room right away.

Overdose Management Protocol

There is no specific treatment or antidote available for a rosuvastatin overdose. Management is therefore entirely symptomatic and supportive. The regulatory context also notes that standard procedures like hemodialysis do not significantly enhance the clearance of rosuvastatin from the body. Consequently, management focuses on general hospital monitoring and observation.

Therapeutic Uses of Roxera

Quick Facts: Therapeutic Overview

  • Addresses: High cholesterol (hyperlipidemia) and mixed dyslipidemia.
  • Benefit: May help reduce the risk of certain cardiovascular events, including heart attack and stroke.
  • Treats: Primary dysbetalipoproteinemia and elevated triglycerides.
  • Usage: Adjunctive therapy to diet and non-pharmacological interventions.

Roxera (rosuvastatin) is indicated as a recognized therapeutic option used in conjunction with dietary modifications to manage lipid levels in the blood. It is a standard treatment for adult patients who present with primary hyperlipidemia and mixed dyslipidemia. The medication is used to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol), and triglycerides.

In addition to addressing cholesterol and triglyceride levels, Roxera may help increase levels of high-density lipoprotein cholesterol (HDL-C, or “good” cholesterol). This medication is also indicated for the management of primary dysbetalipoproteinemia and can be used as an adjunct to diet for adult patients with hypertriglyceridemia. Furthermore, the therapeutic effect of Roxera may assist in slowing the progression of atherosclerosis in adult patients.

In patients identified as being at increased risk for cardiovascular events, Roxera may help reduce the risk of major events, including stroke and myocardial infarction. It is also used in pediatric patients with specific types of familial hypercholesterolemia.


Eligibility and Restrictions for Use

Roxera's eligibility is strictly defined by government regulatory documents, outlining who may use the medicine and who is prohibited from use.

Eligibility Scope

Eligibility Status Key Population Groups (Adults and Pediatric)
Populations Allowed Adults for all approved indications. Pediatric patients (children/adolescents) with Heterozygous or Homozygous Familial Hypercholesterolemia (starting at age 6 to 8)
Populations Not Recommended Children younger than 6 years (safety not established)

Contraindications and Restrictions

  • Absolute Contraindications: Roxera is contraindicated in patients with active liver disease, including unexplained elevations of liver enzymes. Use is also prohibited in patients with a known hypersensitivity to rosuvastatin or any component of the formulation.
  • Pregnancy and Lactation: Use is contraindicated during pregnancy and lactation. Females of reproductive potential must use effective contraception during treatment.
  • Condition-Specific Restrictions: The maximum 40 mg dose is contraindicated in patients with factors pre-disposing them to myopathy (e.g., uncontrolled hypothyroidism) and in those of Asian ancestry due to documented higher systemic exposure. Patients with severe renal impairment (CrCl < 30 mL/min) are generally contraindicated from use.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use this medicine by establishing non-negotiable contraindications based on physiological states like pregnancy and active liver disease, and by defining restricted eligibility through age thresholds and comorbidity-linked limitations that prohibit the maximum 40 mg dose in at-risk groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Roxera's interaction profile is officially documented and defined by specific pharmacological constraints and restrictions. Co-administration with Gemfibrozil should be avoided due to a significant increase in Rosuvastatin exposure and a heightened risk of adverse skeletal muscle effects. Use with specific combination antivirals, such as Sofosbuvir/Velpatasvir/Voxilaprevir, is also formally not recommended.


The primary mechanism for clinically significant drug-drug interactions is the inhibition of drug transporters (OATP1B1 and BCRP). Because Rosuvastatin is a substrate for these transporters, co-administration with inhibitors, such as Cyclosporine or certain antivirals, leads to increased Rosuvastatin plasma concentrations. This regulatory constraint mandates specific dose limitations; for instance, the Rosuvastatin dose must not exceed 5 mg daily when taken with Cyclosporine.


Additive pharmacodynamic risk requires caution when Rosuvastatin is combined with other fibrates or high-dose Niacin (ge 1 g/day), as this combination increases the risk of myopathy. When co-administered with Coumarin Anticoagulants (e.g., Warfarin), the International Normalized Ratio (INR) is prolonged, requiring official regulatory monitoring until stable. A mandatory timing rule dictates that Rosuvastatin must be administered at least 2 hours after aluminum and magnesium hydroxide antacids. Patients who consume substantial quantities of alcohol or have chronic alcohol liver disease may have an increased risk for hepatic injury. Furthermore, regulatory documents note that Asian patients may experience an approximately 2-fold increase in Rosuvastatin systemic exposure.

Mechanism of Action

Roxera (Rosuvastatin) operates through two parallel mechanistic domains centered on hepatic (liver) action and vascular modulation.

Inhibiting Cholesterol Synthesis and Enhancing Clearance

The drug acts as a competitive inhibitor of the enzyme HMG-CoA reductase, which controls the rate-limiting step in the Mevalonate pathway. This molecular inhibition reduces the synthesis of cholesterol in the liver, which triggers a crucial compensatory feedback: the upregulation of LDL receptors on the liver surface. This process enhances the liver's capacity to extract Low-Density Lipoprotein Cholesterol (LDL-C) from the systemic circulation, resulting in a reduction in plasma LDL-C levels.

Modulating Vascular Health

Beyond lipid dynamics, Roxera engages in a secondary mechanism by reducing the production of specific isoprenoid intermediates. This action indirectly limits the activation of certain signaling proteins (GTPases) essential for vascular cell activity. This cascade influences endothelial function and reduces pro-inflammatory signaling in arterial walls, influencing the components of atherosclerotic plaque.

Dosage and Administration Information

How to Use Roxera (Rosuvastatin): Official Administration Guidelines

The usage of Roxera is structured as a long-term, once-daily, oral regimen. The guidelines define the exact routes, dosing schedules, and specific conditions for proper administration in clinical practice.


Administration Scope

Instruction Entity Detail
Route of administration: Oral administration via film-coated tablet or capsule containing granules.
Dosing schedule (Adults): Standard starting doses are 10 mg or 20 mg once daily. The dose can range from 5 mg up to a maximum of 40 mg once daily.
Timing in relation to meals: Can be taken with or without food, at any time of day, but should be taken at the same time each day.
Preparation requirements: The film-coated tablet must be swallowed whole and should not be crushed or chewed.
Age-group administration rules: A starting dose of 5 mg is generally considered for older adults (70 years or older) and patients with severe renal impairment.
Missed-dose rules: If a dose is missed, treatment should be resumed with the next scheduled dose; a patient should not take two doses at the same time.
Special procedural conditions: The medicine must be administered at least 2 hours before taking aluminum and magnesium hydroxide antacids.

Connection to the Overall Use Protocol

The guidelines establish a standardized, once-daily oral regimen for continuous therapy. This protocol defines the precise initial dose, the requirement to adjust the dosage based on follow-up assessments (typically every 2 to 4 weeks), and includes specific dose restrictions for certain patient populations to ensure appropriate systemic exposure.

Recent Clinical Evidence

Research evidence / Overview of Studies for Roxera

Evidence for Use in Managing High Cholesterol (Lipid Modification)

The core evidence for Roxera (Rosuvastatin) was evaluated by measuring blood fat levels through Randomized Controlled Trials (RCTs) and comprehensive comparisons against placebo. Research examined changes in specific blood fat markers, including Low-Density Lipoprotein Cholesterol (LDL-C) and Triglycerides, in adult patients with high cholesterol or mixed dyslipidemia. Studies described patterns where the medicine was associated with changes in these lipid markers, which research examined in relation to the dosage used. Findings indicate that changes in lipid marker levels were observed and maintained across the short and intermediate timeframes of the clinical trials.

Evidence for Preventing Major Cardiovascular Events

Beyond its evaluation for changes in cholesterol levels, Rosuvastatin was studied in trials exploring its association with the occurrence of major cardiovascular events, such as a first heart attack or stroke, in individuals identified as being at increased risk. This evidence is primarily drawn from large-scale, placebo-controlled RCTs. Reports from the landmark trials, such as the JUPITER trial, described a pattern where the incidence of these major cardiovascular events was observed to be lower in the group receiving the study medicine compared to the group receiving a placebo within the specific high-risk populations studied. A key limitation is that the results apply most directly to the highly defined population included in the main trials.

Evidence in Special Populations (Pediatric)

Rosuvastatin was evaluated in a specialized population of children and adolescents diagnosed with inherited forms of high cholesterol, specifically Heterozygous Familial Hypercholesterolemia (HeFH). Researchers conducted small, controlled, multi-center trials focused on how the medicine affected blood fat markers in this younger age group. Data for certain groups remain insufficient due to the small total sample size of pediatric patients studied. Follow-up durations were limited in comparison to the long period over which these patients will be living with the condition.

Frequently Asked Questions (FAQ)

Common questions about Roxera (FAQ)


Q: How quickly do people typically start to feel the effects of Roxera?

A: As Roxera works to change blood fat levels, the effects are generally not noticeable by the user. Official dosing guidance indicates that blood lipid levels should be analyzed and the dosage adjusted, if necessary, within 2 to 4 weeks after starting Roxera or changing the dose.


Q: What does it mean if a regulatory agency has issued a safety warning about Roxera?

A: Official regulatory documents classify safety information using terms like 'Contraindication' and 'Warning'. A contraindication means that the medicine is prohibited under specific conditions, such as active liver disease. A warning indicates that a serious risk, such as severe muscle breakdown or liver enzyme elevations, is possible and should be monitored by a healthcare provider.


Q: Can Roxera still be used if a person has certain kidney issues?

A: Regulatory documents acknowledge the need for specific guidance for individuals with kidney issues. Official guidance addresses the use of Roxera in individuals with severe renal impairment and indicates that dose limitations apply.


Q: Is there any research evidence on using Roxera in the elderly?

A: Regulatory information notes that advanced age (generally considered 65 years and older) is recognized as a factor that may increase the potential for muscle-related side effects. Due to this recognized consideration, official guidelines advise caution and may involve a specific starting amount for older adults.


Q: Why do doctors refer to Roxera as a long-term treatment?

A: The medicine is officially indicated for use alongside diet to manage blood fat levels. In some studies, its use has been described as slowing the progression of atherosclerosis (hardening of the arteries), necessitating continuous, long-term administration as a management strategy.


Q: Does Roxera have a black box warning in the U.S. and what does that mean?

A: The official U.S. regulatory filings for Rosuvastatin do not include a Black Box Warning (BBW). The label lists serious risks, such as rhabdomyolysis (severe muscle breakdown), under the Warnings and Precautions section.


Q: What are the differences between the various strengths of Roxera?

A: Dosing is determined by a healthcare provider based on a person's lipid goals and clinical factors. Regulatory documents indicate that the highest available strength is specifically reserved only for patients who have not achieved their treatment goals using lower strengths.


Q: What are the most common reasons people need to stop using Roxera?

A: Clinical trials reported that the most frequent documented adverse reactions leading to discontinuation were myalgia (muscle pain), abdominal pain, and nausea. A healthcare provider assesses the necessity of discontinuing use based on these and other documented adverse reactions.


Q: What does the term 'contraindication' mean regarding who cannot use Roxera?

A: A contraindication is a strict regulatory term meaning that the use of the medicine is prohibited under specific circumstances, such as having active liver disease. This prohibition is due to the high risk associated with use in these defined situations.


Q: Are the safety data for Roxera collected primarily from clinical trials?

A: Official safety data in regulatory documents is collected from multiple sources. Adverse reactions are listed based on frequency reported in both controlled clinical trials and information gathered from postmarketing experience (reports submitted after the medicine has been in use).


Q: Is Roxera described as a curative treatment or a management tool?

A: Roxera is indicated in official documents as an adjunct to diet and is primarily intended to slow the progression of a condition. This function classifies it as a management tool used for continuous, long-term care rather than a treatment intended to provide a cure.


Q: Can Roxera affect sleep patterns?

A: Postmarketing reports list sleep disorders—including insomnia (difficulty falling or staying asleep) and nightmares—as being associated with the medicine, though the frequency with which these occur is not known.


Q: What foods or drinks should people be cautious about consuming while using Roxera?

A: Official product information notes that caution is advised regarding alcohol consumption, as it may increase the risk of liver injury. Additionally, official documents indicate that Roxera must be separated by at least two hours from antacids containing aluminum and magnesium hydroxide.


Q: Does Roxera interact with common over-the-counter pain relievers?

A: The primary focus of regulatory interaction warnings is on medicines that significantly increase the concentration of Roxera in the blood or increase the risk of muscle effects. Official documents address interactions with prescription anticoagulants, but they do not specifically list common OTC pain relievers as major interactions.


Q: Is Roxera known to interact with birth control pills?

A: Official product information advises that women of childbearing potential should use effective contraception during use. Regulatory data also show that co-administration of Roxera increases the plasma concentrations of certain oral contraceptives.


Q: How long is the duration of action for Roxera after one use?

A: Official pharmacological data show that the elimination half-life of the active component is approximately 19 hours. This figure supports the medicine's design for a consistent once-daily regimen.


Q: Can a person stop using Roxera suddenly?

A: Regulatory documents mention that prompt discontinuation of use is advised if a person experiences unexplained muscle pain, tenderness, or weakness. This is because these symptoms may indicate a more serious adverse reaction.


Q: Does Roxera require blood tests while it is being used?

A: Official documents recommend that liver enzyme testing be considered before starting Roxera and when clinically necessary. Additionally, blood lipid levels must be analyzed after initiation and dose changes to ensure treatment goals are being met.


Q: Are there different brand names or generic versions of Roxera?

A: The active ingredient in Roxera is Rosuvastatin calcium, and the original brand name is Crestor. Since the patent expiry, generic versions of Rosuvastatin tablets have been approved by regulatory agencies and are available.


Q: Do people typically use Roxera with other medicines?

A: Yes, official documents indicate that Roxera is often used as an adjunct to diet and may also be used as an adjunct to other LDL-C-lowering therapies, particularly in individuals with certain inherited forms of high cholesterol.


Q: What is the distinction between a major and a minor interaction listed for Roxera?

A: Regulatory documents do not formally classify interactions as 'major' or 'minor.' Instead, interactions are functionally classified by the required action, ranging from avoiding concomitant use (due to high risk) to limiting the Roxera dose to manage potential risks.


Q: Can Roxera cause dizziness or lightheadedness?

A: Adverse reaction data collected from clinical trials reports that dizziness was noted as a possible side effect of Roxera. Any feeling of lightheadedness is a documented observation.


Q: Is there a maximum amount of time a person can use Roxera?

A: There is no specific maximum duration of use cited in regulatory information. As the medicine is used for the long-term management of cardiovascular risk factors, it is intended for long-term, continuous use as directed by a healthcare provider.


Q: Are there any general safety classifications for Roxera described by government agencies?

A: Yes, regulatory agencies apply specific safety classifications. Roxera is officially contraindicated during pregnancy. It was formerly categorized as a Pregnancy Category X drug, which indicated a high risk to the fetus.


Q: Are there specific vitamins or minerals that Roxera may interact with?

A: Official information states that combining the medicine with high doses of Niacin (Vitamin B3) increases the potential for muscle effects. Additionally, antacids containing aluminum and magnesium minerals require specific timing to avoid interaction.


Q: Does Roxera interact with common anti-depressants or anti-anxiety medications?

A: While the primary drug interactions listed focus on strong inhibitors of specific liver enzymes and transporters, the label does not specifically name common anti-depressants or anti-anxiety medications. Regulatory guidance on drug interactions should always be reviewed by a healthcare professional.

How should Roxera be stored and disposed of?

Official Storage and Disposal Instructions for Roxera (Rosuvastatin)

Official regulatory documents define specific conditions for storing and disposing of rosuvastatin tablets to ensure stability and public safety. All statements are strictly based on government-approved labeling.


Required Storage Conditions

Requirement Official Statement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from moisture and kept in a dry place.
Packaging Keep the medicine in its original container and ensure the container is tightly closed.
Safety Store out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Roxera must be disposed of according to local requirements for pharmaceutical waste. Regulatory guidelines explicitly state that the tablets must not be disposed of via wastewater or regular household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roxera found in:

A-Z Index: